Insider Buying: Fractyl Health, Inc. (NASDAQ:GUTS) Director Acquires 16,129 Shares of Stock

Fractyl Health, Inc. (NASDAQ:GUTS) Director William Bradley purchased 16,129 shares of Fractyl Health stock in a transaction dated Thursday, March 13th. The shares were bought at an average cost of $1.26 per share, for a total transaction of $20,322.54. Following the transaction, the director now directly owns 16,129 shares of the company’s stock, valued at approximately $20,322.54. The trade was a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Fractyl Health Stock Performance

Shares of GUTS stock opened at $1.27 on Tuesday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The company’s 50-day simple moving average is $1.64 and its 200-day simple moving average is $2.16. Fractyl Health, Inc. has a one year low of $1.16 and a one year high of $8.37. The stock has a market capitalization of $62.13 million and a price-to-earnings ratio of -0.10.

Fractyl Health (NASDAQ:GUTS) last issued its earnings results on Monday, March 3rd. The company reported ($0.52) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.08). Equities analysts anticipate that Fractyl Health, Inc. will post -1.61 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Morgan Stanley reduced their price target on shares of Fractyl Health from $18.00 to $10.00 and set an “overweight” rating on the stock in a research report on Monday, February 3rd.

Hedge Funds Weigh In On Fractyl Health

A number of large investors have recently bought and sold shares of the business. Massachusetts Financial Services Co. MA lifted its holdings in Fractyl Health by 4.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock worth $2,646,000 after acquiring an additional 49,289 shares during the last quarter. 683 Capital Management LLC lifted its holdings in Fractyl Health by 4.0% in the fourth quarter. 683 Capital Management LLC now owns 650,000 shares of the company’s stock worth $1,339,000 after acquiring an additional 25,000 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Fractyl Health by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 513,079 shares of the company’s stock valued at $1,057,000 after buying an additional 11,603 shares during the last quarter. Silverarc Capital Management LLC raised its holdings in shares of Fractyl Health by 6.2% during the fourth quarter. Silverarc Capital Management LLC now owns 176,922 shares of the company’s stock valued at $364,000 after buying an additional 10,256 shares during the last quarter. Finally, State Street Corp raised its holdings in shares of Fractyl Health by 129.4% during the third quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after buying an additional 63,968 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.